Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories (NYSE:ABT) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.

Abbott facts

Headquarters (founded)

Abbott Park, Ill. (1888)

Market Cap

$52.6 billion


Health care equipment

Trailing-12-Month Revenue

$39.4 billion


Chairman/CEO Miles White (since 1999)
CFO Thomas Freyman (since 2001)

Return on Equity (average, past 3 years)



$11.5 billion / $16.3 billion

Dividend Yield



Johnson & Johnson (NYSE:JNJ)
Merck (NYSE:MRK)
Sanofi (NYSE:SNY)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 2,658 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.

A couple of months ago, one of those Fools, BuilderJS, succinctly summed up the Costco bull case for our community:

Compelling business model -- limited selection focused on value to the customer. Outstanding leadership and corporate culture that promotes business continuity. Excellent execution -- from the top notch merchandising, to the ability to negotiate with suppliers to the responsible growth plans.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.